Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib

• Published in: Retina (Philadelphia, Pa.) Vol. 31; no. 6; p. 1028
• Main Authors: Choi, Daniel Y, Ortube, Maria Carolina, McCannel, Colin A, Sarraf, David, Hubschman, Jean-Pierre, McCannel, Tara A, Gorin, Michael B
• Format: Journal Article
• Language: English
• Published: United States 01.06.2011
• Subjects: Aged, 80 and over; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Antihypertensive Agents - therapeutic use; Aptamers, Nucleotide - adverse effects; Bevacizumab; Female; Filtering Surgery; Humans; Intraocular Pressure - drug effects; Intravitreal Injections; Macular Degeneration - drug therapy; Male; Ocular Hypertension - chemically induced; Ocular Hypertension - therapy; Ranibizumab; Retreatment; Retrospective Studies; Tonometry, Ocular; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity
• ISSN: 1539-2864
• DOI: 10.1097/iae.0b013e318217ffde

To investigate elevated intraocular pressures (IOP) (defined by a measurement >25 mmHg at a follow-up visit) after an intravitreal injection of anti-vascular endothelial growth factor agents for age-related macular degeneration. Retrospective review of medical records. A total of 127 patients (155 eyes) received an intravitreal injection of anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab, or pegaptanib) ranging from 1 to 39 injections for more than a period of 30 to 1759 days. Among this population, 12 patients (14 eyes; 9.4%) developed elevated IOP >25 mmHg. Of these, 7 patients (5.5%) developed sustained elevated IOP (IOP >25 mmHg on 2 separate visits requiring glaucoma medication or surgery), of which 8 eyes required topical medications and 1 eye underwent glaucoma surgery. Mean IOP of injected eyes receiving intravitreal injection was 15.2 ± 2.4 mmHg, and the mean IOP was 14.9 ± 2.6 mmHg for noninjected eyes. Among eyes that had elevated IOPs, there was no association with injection frequency, number of injections, or anti-vascular endothelial growth factor agent used. Elevated IOP, sustained or unsustained, after intravitreal injection is not uncommon. No association with patient demographics or injection history was identified in the authors' study population.